image of silk fabric and dry skin
Drug ClassGeneric/Trade
Company Names
IndicationApproving
Regulatory Agency
Antiaging
Treatments
Clindamycin Foam 1%
Aluma®Skin Renewal System with FACES™
Lumenis
Approved for the noninvasive treatment of fine lines
and wrinkles.
US FDA
Antibacterial
Agents
Meropenem for Injection
MERREM®
AstraZeneca
Approved for the noninvasive treatment of fine lines and wrinkles.US FDA
Moxifloxacin HCl
Avelox®
Bayer HealthCare Schering-Plough
Approved for the treatment of complicated skin and
skin structure infections in adults and children.
US FDA
Tygacycline
Tygacil®
Wyeth
Approved for the treatment of complicated skin
and skin structure infections in adults that are
caused by methicillin-susceptible Staphylococcus
aureus, Escherichia coli, Klebsiella pneumoniae,
or
Enterobacter cloacae.
US FDA
EMEA
Antifungal AgentsCiclopirox Topical Suspension 0.77%
Taro Pharmaceuticals
Abbreviated NDA approved for the treatment of fungal infections of the skin. It is
the bioequivalent of Medicis Pharmaceutical’s Loprox® Topical Suspension 0.77%.
US FDA
Griseofulvin Oral Suspension USP
Glades Pharmaceuticals
Approved for the treatment of tinea barbae, tinea
capitis, tinea corporis, tinea pedis, and tinea unguium
(onychomycosis).
US FDA
Terbinafine HCl
Lamisil®Tablets
Ranbaxy Laboratories
Approved for the treatment of onychomycosis of
the toenail or fingernail due to dermatophytes (tinea
unguium).
US FDA
AntihistamineDesloratadine Syrup
Clarinex®Reditabs®
Schering-Plough
Reformulated 2.5mg and 5mg tablets approved for
the treatment of allergy symptoms caused by both
perennial indoor and seasonal outdoor allergens and
for chronic idiopathic urticaria, or hives of unknown
cause, in adults and children >6 years of age.
US FDA
Antipruritic AgentsEpinastine HCl 1%
Alesion®Dry Syrup
Nippon
Boehringer Ingelheim/ Sankyo
Approved for the treatment of allergic rhinitis, urticaria,
and pruritus associated with skin diseases such
as eczema and dermatitis in pediatric patients.
Japanese Ministry of Health, Labour and Welfare
Antipsoriatic AgentsClobetasol Propionate 0.05%
Clobex™Spray
Galderma
For the treatment of moderate-to-severe plaque psoriasis. Clobex® is
already available as a lotion and shampoo.
US FDA
Efalizumab
Raptiva®
Serono
Approved for the treatment of moderate-to-severe chronic plaque psoriasis in
adults >18 years of age who are candidates for systemic therapy or phototherapy.
TPD Canada
Etanercept
Enbrel®
Amgen/ Wyeth Pharmaceuticals
Approved for the treatment of moderate-to-severe psoriasis in adults.TPD Canada
Fluocinonide 0.1%
Vanos®
Cream Medicis Pharmaceuticals
A new class I topical corticosteroid approved for the treatment of plaque-type
psoriasis affecting up to 10% of the body surface area.
US FDA
Infliximab
Remicade®
Centocor/ Schering-Plough
Approved for the treatment of moderate-to-severe plaque
psoriasis in adults who failed to respond to, or have a
contraindication to, or are intolerant of other systemic
therapies including cyclosporine, methotrexate, or PUVA.
EMEA
Atopic Dermatitis AgentsFluticasone Propionate 0.05%
Cutivate®Lotion
Pharmaderm/Altana
Approved in patients >1 year of age for the treatment of atopic dermatitis.US FDA
Hydrogel Dressing
MimyX®Cream
Stiefel Laboratories
A topical nonsteroidal cream approved for the treatment of atopic dermatitis.US FDA
HIV/AIDSEmtricitabine
Emtriva™Oral Solution
Gilead Sciences
Approved for use in combination with other antiretroviral
agents for the treatment of HIV-1 infection in
patients >3 months of age.
US FDA
Tipranavir Capsule
Aptivus®
Boehringer Ingelheim Pharmaceuticals
Accelerated approval for this nonpeptide protease
inhibitor as a combination antiretroviral treatment of
HIV-1 infected adult patients with evidence of viral
replication, and who are highly treatment-experienced
or have HIV-1 strains resistant to multiple protease
inhibitors. The approved dose is 500mg taken with
200mg ritonavir twice daily
US FDA
EMEA
LeishmaniasisMiltefosine
Impavido™
AEterna Zantaris
Approved for the treatment of the cutaneous form
of leishmaniasis as well as the visceral form of this
condition.
Columbian Food and Drug Agency
Oncologic
Agents
Imiquimod 5%
Aldara™Cream
3M
Approved for the treatment of superficial basal cell
carcinoma.
TPD Canada
Psoriatic Arthritis AgentsAdalimumab
Humira™
Abbott Laboratories
Approved for the treatment of psoriatic arthritis.US FDA
Etanercept
Enbrel®
Amgen/ Wyeth Pharmaceuticals
Approved for the improvement of physical function in patients with psoriatic arthritis.US FDA
Infliximab
Remicade®
Centocor/ Schering-Plough
Approved for the treatment of psoriatic arthritis.US FDA
RosaceaMetronidazole Topical Gel 1%
MetroGel®
Galderma Laboratories LP
Approved for the topical treatment of inflammatory lesions of rosacea.US FDA
VaccinesMeasles, Mumps, Rubella, and Varicella Virus Vaccine, Live
ProQuad®
Merck
Approved for simultaneous vaccination against measles,
mumps, rubella, and varicella in children 12 months to 12
years of age.
US FDA
EMEA
Wound ManagementAntimicrobial Barrier Dressing
ACTICOAT*
Moisture Control Smith & Nephew
Approved for wound care as a barrier to bacterial
penetration, featuring the patented Silcryst™
nanocrystalline silver technology.
US FDA